Mr. Zuga is a founder and managing member of Red Abbey. From May 2000 to December 2003, Mr. Zuga was a Managing Director in the investment banking department of Legg Mason Wood Walker, Inc. and the Head of the Life Sciences Group. Under his leadership, Legg Mason executed 22 financings and raised more than $1 billion for life sciences companies since January 1, 2000. Mr. Zuga was primarily responsible for the creation of the Life Sciences Investment Banking Group and developed relationships with a select group of companies in four distinct areas: biotechnology, specialty pharmaceuticals, drug discovery and genomics. In this position, Mr. Zuga acquired significant expertise in assessing life sciences business models by working with product companies (biologicals and small molecules), research and development companies, chemistry companies, drug delivery companies and platform technology companies. In less than three years, Mr. Zuga met with and evaluated more than 75 publicly-traded and 500 privately-held life sciences companies. From 1999 to 2000, Mr. Zuga was one of two Principals in Legg Mason’s Health Care Investment Banking Group, where he was responsible for building a presence in the life sciences industry, with a primary focus on new business development. Mr. Zuga’s secondary responsibilities included providing support in select areas of health care services and e-commerce. From 1996 to 1999, Mr. Zuga was a Vice President in Legg Mason’s Health Care Investment Banking Group, with primary responsibility for transaction execution, which included structuring and marketing transactions, leading the due diligence effort and obtaining approval from Legg Mason’s Commitment Committee. Mr. Zuga’s new business development initiatives included a comprehensive calling program on health care companies based in Nashville, TN and a preliminary effort in life sciences. In 1993, Mr. Zuga joined Legg Mason Wood Walker, Inc. as an Associate in the investment banking department. From 1993 to 1996, Mr. Zuga performed a generalist role in a full service investment banking group and gained significant industry experience in health care and real estate, assisting in the execution of public and private offerings of equity and debt, and mergers and acquisition assignments. Over more than ten years at Legg Mason, Mr. Zuga worked on a wide variety of investment banking transactions for a well-diversified group of clients. Mr. Zuga’s life sciences clients included Ceregene, Inc., Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN), Genaissance Pharmaceuticals, Inc. (where Kevin Rakin, a co-founding member of the CEO’s Council is President and CEO, and Skip Klein, a Venture Partner, is a member of the Board of Directors), Idun Pharmaceuticals, Inc., Indevus Pharmaceuticals, Inc. (NASDAQ: IDEV), IntraBiotics Pharmaceuticals, Inc. (NASDAQ: IBPI), Mitokor, Inc., Novalon Pharmaceutical Corp., Palatin Technologies, Inc. (AMEX: PTN), Telik, Inc. (NASDAQ: TELK) and Therion Biologics Corp. Mr. Zuga has developed relationships with some of the best life sciences venture capital firms in the United States and Europe, including Alta Partners, Bear Stearns Health Innoventures, Canaan Partners and HBM BioVentures. Mr. Zuga’s prior work experience includes positions at Raymond James & Associates, Inc. (investment banking), Southeast Bank, N.A. (commercial lending), IBM Corporation (finance department) and General Motors Corporation (industrial engineering). From 1985 to 1991, Mr. Zuga was a member of the United States Air National Guard (Ohio and Florida). Mr. Zuga received an MBA from the Kenan-Flagler Business School at the University of North Carolina at Chapel Hill in 1993 and a BS in Business Administration/Finance from The Ohio State University in 1988

Matt Zuga
Managing Director
Red Abbey Venture Partners

If you are interested in learning more about TIGER 21, please complete the contact form and you will receive a copy of our most recent Asset Allocation Report.

randomness